Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Pseudoephedrine · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Arm 2 | ACTIVE_COMPARATOR | - |
| Arm 3 | ACTIVE_COMPARATOR | - |
| Arm 4 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Acetylsalicylic Acid (Aspirin Complex, BAYE4465) + Pseudoephedrine | DRUG | Single oral dose of 1 to 2 Aspirin Complex sachets, each containing granules of 500 mg Acetylsalicylic Acid (ASA) and 30 mg Pseudoephedrine (PSE), to be taken orally after dissolving in a glass of water; to be repeated as needed every 6 hours for a period of not more than 3 days. |
| Acetylsalicylic Acid (Aspirin, BAYE4465) | DRUG | Single oral dose of 1 to 2 sachets Acetylsalicylic Acid, each containing granules of 500 mg Acetylsalicylic Acid (ASA), to be taken orally after dissolving in a glass of water; to be repeated as needed every 6 hours for a period of not more than 3 days. |
| Pseudoephedrine | DRUG | Single oral dose of 1 to 2 sachets Pseudoephedrine, each containing granules 30 mg Pseudoephedrine, to be taken orally after dissolving in a glass of water; to be repeated as needed every 6 hours for a period of not more than 3 days. |
| Placebo | DRUG | Single oral dose of 1 to 2 sachets, each containing Placebo granules, to be taken orally after dissolving in a glass of water; to be repeated as needed every 6 hours for a period of not more than 3 days. |
Inclusion Criteria:- Male and female subjects between 18 and 65 years of age.- Onset of cold symptoms within 96 hours (4 days) before study participation.- Current complaint of at least moderate sore throat at baseline- Current complaint of at least moderate NC at baseline- History of other symptoms...
Pseudoephedrine is a small molecule drug being developed by Bayer AG for the treatment of the common cold. It is currently in Phase 3 clinical development, meaning it is investigational and not yet approved. The drug is being studied for its efficacy and tolerability in patients with common cold and pharyngitis.
Pseudoephedrine is a decongestant that works by narrowing the blood vessels in the nasal passages, reducing swelling and congestion. It is being studied in combination with aspirin for the treatment of common cold symptoms. The drug is in Phase 3 clinical trials to assess its efficacy and tolerability.
Pseudoephedrine is being developed by Bayer AG, a multinational pharmaceutical company. Bayer AG is listed on the stock exchange under the ticker BAYRY. The drug is currently in Phase 3 clinical development for the treatment of the common cold and pharyngitis.
Pseudoephedrine is in Phase 3 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. The Phase 3 trial, NCT01062360, has been completed and enrolled 1,016 participants to evaluate the efficacy and tolerability of aspirin plus pseudoephedrine for common cold and pharyngitis.
Pseudoephedrine has one completed Phase 3 clinical trial, NCT01062360, titled 'Placebo and Active Controlled Study to Assess Efficacy and Tolerability of Aspirin Plus Pseudoephedrine.' This randomized, double-blind, placebo-controlled trial enrolled 1,016 participants with common cold and pharyngitis across the United States, Italy, Poland, and Slovakia.
Pseudoephedrine is a specific decongestant drug being studied by Bayer AG for the common cold. It is being evaluated in combination with aspirin in a Phase 3 clinical trial. The drug is not approved and remains in clinical development, with its safety and efficacy still being assessed.